Externally Sponsored Research
Externally Sponsored Research supports independent researchers and external sponsors studying Gilead products or therapeutic areas to expand medical knowledge, inform care and improve patients’ lives.
This grant was recently updated
Gilead removed the Hepatitis B and Hepatitis C Topics of Interest, both previously accepting concepts on a rolling basis until funds were exhausted. The removed topics covered updated HBV treatment guidelines and shared decision-making, and coordinated care and treatment for HCV-positive pregnant patients.
Funder: Gilead Sciences
Due Dates: RFP Programs: topic-specific submission windows | RFP Topics of Interest: longer windows or until funds are dispersed
Funding Amounts: Funding and/or study drug support for research activities
Summary: Supports third-party research on Gilead products or therapeutic areas to inform clinical decisions and improve patients’ lives.
Key Information: Investigator Initiated Research involving a Gilead product must follow regulatory approval in the study country.
Description
Gilead Sciences’ Externally Sponsored Research program supports scientifically relevant, high-quality research conducted by third parties on Gilead products or therapeutic areas. Its goal is to contribute knowledge to the medical community, inform clinical decision-making and improve patients’ lives. Therapeutic areas include HIV, viral hepatitis, emerging viruses, fungal diseases, solid tumors, and inflammatory and fibrotic diseases.
Support is available through Investigator Initiated Research and Collaborative Research. Requests for Proposals (RFPs) address unmet patient needs in specific populations through innovative approaches to screening, diagnosis and care, while generating insights into disease epidemiology and treatment. Gilead also supports research sponsored by government organizations, nonprofits and pharmaceutical companies, as well as research focused on and led by community organizations.
